SCHEMBL21626290

SCHEMBL21626290

COC(=O)c1c2c(c(N)c3c1CCC3)CCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 12/20 0.48
▸ KDM4E B2RXH2 8/20 0.48
▸ HPGD P15428 5/20 0.48
▸ HSD17B10 Q99714 5/20 0.48
▸ GAA P10253 4/20 0.48
▸ CASP1 P29466 2/20 0.48
▸ CASP7 P55210 2/20 0.48
▸ USP2 O75604 3/20 0.46
▸ MAPK10 P53779 1/20 0.44
▸ MAPT P10636 6/20 0.42
▸ POLB P06746 2/20 0.42
▸ MCL1 Q07820 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ACHE P22303 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24592591 0.83 USP2 (0.45) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL23957355 0.77 MAPT (0.41) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL23063279 0.77 KDM4E (0.39) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2474533 0.74 ACHE (0.46) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL23379153 0.73 USP2 (0.44) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL13104836 0.73 ACHE (0.57) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2181401 0.73 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL15358293 0.73 CA12 (0.48) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL3987143 0.72 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL1506559 0.72 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115618-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2025-04-10 — — US disclosed
US-12234245-B2 Sulfonimidamide compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2025-02-25 — — US disclosed
US-20210253596-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2021-08-19 — — US disclosed
US-20210253596-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2021-08-19 — — US disclosed
EP-3823974-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY F. Hoffmann-La Roche AG (CH) 2021-05-26 — — EP disclosed
CN-112513048-A Sulfonylimide compounds as inhibitors of interleukin-1 activity 豪夫迈·罗氏有限公司 2021-03-16 — — CN disclosed
WO-2020018975-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2020-01-23 — — WO disclosed
WO-2020018975-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2020-01-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115618-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1A, IL18, IL1B ALDH1A1 1225/4885KDM4E 3731/4885HPGD 1781/4885
US-20210253596-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1A, IL18, IL1B ALDH1A1 1225/4885KDM4E 3731/4885HPGD 1781/4885
US-12234245-B2 Sulfonimidamide compounds as inhibitors of interleukin-1 activity IL1A, IL18, IL1B ALDH1A1 1225/4885KDM4E 3731/4885HPGD 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback